INRAYUS
Live / Applied — First extension granted (statement of use) (as of 17 Nov 2025)
What this means for you
Not registered yet, but its 30 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98673823
- Mark type
- Stylized text
- Filed
- 30 Jul 2024
- Published for opposition
- 02 Sept 2025
- Attorney of record
- Jeffrey R. Cadwell
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treating central nervous system diseases or disorders; pharmaceutical preparations for treating schizophrenia; pharmaceutical preparations for treating cognitive disorders; pharmaceutical preparations for treating major depressive disorder; pharmaceutical preparations for treating generalized anxiety disorder
Owner
- Sumitomo Pharma America, Inc., Marlborough, MA, US
- Sumitomo Pharma America, Inc., Marlborough, MA, US
Prosecution history
- 18 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Nov 2025 — SOU EXTENSION 1 GRANTED
- 17 Nov 2025 — SOU EXTENSION 1 FILED
- 17 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 28 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Sept 2025 — PUBLISHED FOR OPPOSITION
- 27 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 31 Jul 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 31 Jul 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 31 Jul 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 26 Mar 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 26 Mar 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 10 Feb 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED